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Zhao Hong4 and Cunchuang Wang1*
Abstract
Background: Laparoscopic metabolic surgery has been previously shown to be an effective treatment for obese
patients with type 2 diabetes (T2DM). The objective of this scoping review is to determine the impact of metabolic
surgery for the treatment of type 2 diabetes in Asia and perform an evidence-based analysis.
Methods: We performed a literature search in PubMed for research on laparoscopic metabolic surgery for the
treatment of T2DM in Asia region. We classified the included studies based on the Oxford Center for Evidence
Based Medicine guidelines. And performed and evidence analysis.
Results: In total, 205 articles were identified. 62.9% of the studies were from East Asia. The evidence of 26
studies are level I, 59 are level II. Laparoscopic sleeve gastrectomy (LSG) was the most commonly reported
surgical procedure (63.1%) in Asia. The number of laparoscopic metabolic surgery for T2DM in Asian countries
has increased rapidly over the last 8 years. We identified 16 studies which showed that laparoscopic metabolic surgery
is an effective and safe treatment for T2DM in patients with a BMI of > 25 kg/m2 to < 35 kg/m2 in Asia.
Conclusions: Our results suggest that laparoscopic metabolic surgery might be an effective and safe treatment for
T2DM patients with BMI < 35 kg/m2, and that LSG is the most commonly performed surgical procedure for this in Asia.
Keywords: Metabolic surgery, Type 2 diabetes, Obesity, BMI < 35 kg/m2, evidence-based analysis
Background
The prevalence of type 2 diabetes mellitus (T2DM) and
obesity is increasing rapidly worldwide, especially in de-
veloping countries [1]. The International Diabetes
Federation reportedin 2015 that there were 450 million
diabetic patients globally [2]. 85–95% of the patients had
T2DM, and 75% were from low-income countries [2].
Ng et al. [3] evaluated that the total number of obese
persons were 671 million all over the world. 13% of
them resided in the United States and 15% in China and
India. Obesity is recognized as one of the major risk fac-
tor for diabetes, coronary heart diseases, stroke, sleep
apnea and cancer [4–6]. It is well known that uncon-
trolled obesity can lead to significant health problems,
decrease life expectancy, and influence quality of life.
Obesity and co-morbid diabetes imposes a significant
global burden to health systems, societies, families, and
individuals affected [7, 8].
Medical therapy can be of limited value in the treatment
of obese patients with T2DM [9–11]. Wittgrove et al. [12]
performed the first five cases of laparoscopic gastric bypass
surgery in 1993–1994 which showed promising results of
weight loss. Since then, laparoscopy has become the main
method of bariatric surgery. In 1995, Walter Porieset al. [13]
found that bariatric surgery can significantly reduce weight.
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In this same study, 83% of T2DM patients, and 98% of pa-
tients with impaired glucose tolerance, experienced postop-
erative normalization of blood sugar, serum insulin, and
glycosylated hemoglobin, following surgery, and a long-term
stabilization of T2DM remission [13]. Evidence shows that
bariatric surgery not only control a patient’s weight, but can
also improve obesity-related complications, including hyper-
tension, hyperlipidemia, snoring, sleep apnea syndrome,
polycystic ovarian syndrome, and other metabolic diseases,
especially T2DM [14–18]. At present, the common meta-
bolic surgical procedures performed are: laparoscopic sleeve
gastrectomy (LSG), laparoscopic adjustable gastric banding
surgery (LAGB), laparoscopic biliopancreatic diversion with
duodenal switch (BPD-DS), and laparoscopic Roux-en-Y
gastric bypass (LRYGB) [19–21]. The most effective meta-
bolic surgical procedures are the RYGB and duodenal switch
[19–21].
Several reports of laparoscopic metabolic surgery for
T2DM are available in different Asian countries. How-
ever, information regarding which surgical methods are
most suitable for T2DM in Asia is scarce. Therefore, we
performed this scoping review and evidence-based ana-
lysis to understand the current and common bariatric
surgical procedures for T2DM in Asia.
Methods
Search strategy
We conducted a literature search from the electronic da-
tabases of PubMed from 1st January, 1994 to 19st
November, 2017. The following key search terms were
used: “bariatric surgery OR metabolic surgery OR obes-
ity surgery OR weight loss surgery” AND “diabetes mel-
litus” AND “names of Asian countries and regions:
according to WHO list of countries and regions.” There
were no language restrictions.
Screening
Three authors were involved in the independent title and
abstract screening of potentially relevant articles. All screen-
ing was performed independently and in duplicate. If there
were any discrepancies between authors and a consensus
was unable to be reached, a fourth author was consulted.
Inclusion and exclusion criteria
Studies describing laparoscopic metabolic surgery for
T2DM, in patients with or without obesity were in-
cluded. Studies were included if they were conducted in
one of 49 Asian countries. We excluded all studies from
non-Asian countries, patients without type 2 diabetes,
and any non-laparoscopic surgeries.
Literature screening and data extraction
Three reviewers (DZ, QR, GB) independently ex-
tracted the following terms from each study: year of
publication, the country of first author, regions (East
Asia, Southeast Asia, South Asia, West Asia, Central
Asia), title, presence of patients with or without
T2DM, language, type of bariatric surgery, and the
type of clinical research (animal trials, basic research).
All data was extracted in duplicate, and any disagree-
ments of data extractionwere resolved through discus-
sion between authors.
Evidence grade criteria and statistical analysis
Three reviewers (DZ, QR, GB) independently classified
the clinical study, using Oxford Center for Evidence Based
Medicine (EBM) Levels of Evidence guidelines (https://
www.cebm.net/2017/05/ocebm-levels-of-evidence/) [22].
Any difference between the reviewers was resolved by dis-
cussion. Data extraction was performed using Microsoft
Excel 2007 software.
Results
Literature search
Our search yielded 919 articles (including 102 systematic
review/meta-analyses, 52 randomized controlled trials
(RCTs), 398 cohort studies, 129 case series, 238 case re-
ports and others) from all over the world, and 205 arti-
cles in Asian countries (including 13 systematic review/
meta-analyses, 10 RCTs, 59 cohort studies, 35 case
series, and 88 case report and others). Of the 205 reports
included, 157 were clinical research, 44 were basic re-
search, and four animal trials. Our study flow diagram is
shown in Fig. 1.
Laparoscopic metabolic surgery for T2DM in Asia
From our search, there is a trend of increased reporting
of literature on laparoscopic metabolic surgery for
T2DM in Asian countries and regions over the past
decade, as shown in Fig. 2.
The distribution of reports on laparoscopic metabolic
surgery for T2DM in Asia
The distribution and proportion studies were: 129
papers from East Asia (62.9%), mostly from China,
Japan, and South Korea; 12 papers from Southeast
Asia (5.9%), located in Singapore, and Malaysia; 29 pa-
pers from South Asia (14.1%), distributed in India; and
34 papers from West Asia (16.5%), representing Israel,
Turkey, and Saudi Arabia. Only one paper represented
Central Asia (0.5%) from Kazakhstan. These results
are presented in Fig. 3.
The level of clinical study on laparoscopic metabolic
surgery for T2DM in Asia
Clinical studies were classified according to the Oxford
Center for EBM Levels of Evidence guidelines: Level I 1a
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(systematic review/ meta-analysis) - 13 articles were
published in Asia out of 102 globally, accounting for
12.7%; Level I 1b (RCT) - 10 out of 52 globally (19.2%);
Level II 2b (cohort study) - 59 out of 398 globally
(14.8%); Level IV 4 (case series) - 35 out of 129 globally
(27.1%). Of the 238 case reports or other articles
published globally representing Level V 5 evidence, 88
were from Asia (37.0%) (Table 1).
The procedures of clinical study on laparoscopic
metabolic surgery for T2DM in Asia
A total of 13,742 patients were reported to have under-
gone laparoscopic metabolic surgery for T2DM from the
included studies in Asia. 3752 (27.3%) cases were
performed by LRYGB, and majority in East Asia (53.2%).
8242 (60.0%) cases by LSG, 70.4% in East Asia. 653
(4.8%) by LGAB, and 1095 (8.0%) by other metabolic
surgery procedures.
Clinical study of laparoscopic metabolic surgery for T2DM
with BMI of > 25 kg/m2 to < 35 kg/m2 in Asia
There were two RCTs, one cohort study, and 14 case
series whereby a total of 507 cases were performed by
LRYGB, 172 by MGB, 107 by LSAGB, 57 by LJISSA and
51 by LSG. 16 studies were on laparoscopic metabolic
surgery for T2DM with BMI of > 25 kg/m2 to < 35 kg/m2
in Asia (Table 2) [22–37]. Thirteen studies were from
China, two from India, and one from South Korea. All the
Fig. 1 Flow diagram of the search process and study classification
Fig. 2 The trends and numbers of literature on laparoscopic metabolic surgery for T2DM in Asia
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16 studies reported a different rate, ranging from 53 to
96.2% of remission of diabetes in patients with T2DM and
BMI of > 25 kg/m2 to < 35 kg/m2. There were no reported
mortalities in any of the trials, post-operative follow-up
times ranging from 1 week up to 5 years (Table 3). More-
over, the major complications were incomplete intestinal
obstruction, mild upper gastrointestinal bleeding, exces-
sive postoperative suture line bleeding with shock, anasto-
motic ulceration, anemia, low albumin, bile reflux, excess
weight loss, early hemorrhage, marginal ulcers, sero-
mas, nausea, vomitingand diarrhea, gastric fistula and
infection, all complications were cured by symptom-
atic treatment (Table 3). These results suggest that
laparoscopic metabolic surgery may be effectively used
to treat T2DM in patients with BMI of > 25 kg/m2
to < 35 kg/m2 in Asia [23–38].
Discussion
This scoping review identified 205 studies of laparo-
scopic metabolic surgery for T2DM in Asia and per-
formed an evidence-based analysis. Most of the studies
were clinical research (78.0%) and published in English
(94.1%) with increasing numbers of publication each
year during the past decade. Using the Oxford Center for
EBM Levels of Evidence, only 12.1% of the studies were
of Level I evidence, mostly conducted in East Asia
(62.1%). LSG was the most commonly reported surgical
procedure, accounting for 64.9% in Asian countries. All
studies reported that laparoscopic metabolic surgery was
safe and effective for T2DM with or without obesity.
There were 16 studies on T2DM with BMI of > 25 kg/m2
to < 35 kg/m2, mostly from China. 70.2% procedures were
LRYGB [23–38]. Our review suggests that laparoscopic
metabolic surgery might be a safe and effective treat-
ment in T2DM patients with BMI from 25 kg/m2 to
35 kg/m2.
This study suggests that the use of laparoscopic meta-
bolic surgery for T2DM is increasing in Asia, especially
in China and India. This may be due to the increasing
number of obese patients in this region. Adela Hruby et
al. [39] reported that from 1980 to 2010, in most Asian
countries and region, the incidence of obesity and over-
weight has increased in both children and adults. Obes-
ity is highly prevalent in China and India, representing a
high proportion of the total number of people with
obesity and diabetes globally [40]. The role of laparo-
scopic metabolic surgery for obesity with T2DM has
been included in many national guidelines in Asia and
Fig. 3 The distribution and rate of literature on laparoscopic metabolic surgery for T2DM in country of Asia. (The initial map courtesy
of "map.ps123.net")
Table 1 The level of included clinical study on laparoscopic metabolic surgery for T2DM
Levels Type of study No. of World No. of Asian Rates
I 1a Systematic review/ meta-analysis 102 13 12.7% (13/102)
I 1b RCT 52 10 19.2% (10/52)
II 2b Cohort study 398 59 14.8% (59/398)
IV 4 Case series 129 35 27.1% (35/129)
V 5 Case report/other 238 88 37.0% (88/238)
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other regions globally [41–43]. The recent increases in
funding investments in medical research in China could
also be a contributing factor to the increase in the num-
ber of studies. The total number of international publi-
cation in China has ranked second in the world in 2015,
which may indicate that there is more scientific activities
being conducted in China [44]. It is reported that there
were 50 million bariatric surgeries globally in 2014, LSG
accounting for 51.7%, RYGB 26.8%, BPD-DS 11.5%, and
AGB 9.5% [45]. The 3rd annual conference of Chinese
Society for Metabolic and Bariatric Surgery in 2015 re-
ported that in China, LSG accounted for 65.5% and
LRYGB 28.9% of bariatric procedures.
Previous studies have shown that LSG is a low-risk,
easy to perform, faster, less expensive, and more effective
weight loss procedure with lower complication rates,
and may have a better safety profile in the short-term
compared to LRYGB [46–48]. However, Li JF et al. [49]
suggested that LRYGB is more effective than LSG for
the treatment of T2DM and metabolic syndrome. Yang
et al. [27] reported in a RCT of 64 patients that both
LSG with LRYGB procedures achieved complete remis-
sion of T2DM with glycated hemoglobin (HbA1c) <6.0%
without taking any diabetic medications. The LRYGB
group had significantly greater weight loss than the SG
group (p = 0.017). A cohort study among 304 patients in-
dicated that LRYGB showed improved effectiveness in
T2DM resolution when compared to LSG at a 5-year
follow-up assessment [50]. Evidence also suggests that
LRYGB could rapidly improve insulin resistance and as-
sociated pancreatic beta-cell function [51, 52]. And both
LSG and LRYGB have been suggested as safe and effect-
ive bariatric procedures for obesity [53]. Therefore,
laparoscopic metabolic surgery has been widely recom-
mended as the most effective treatment for T2DM pa-
tients with BMI ≥ 35 kg/m2 or in patients with one or
more severe obesity-related co-morbidities (T2DM,
hypertension, hyperlipidemia, obstructive sleep apnea,
etc.) [54–57]. Laparoscopic metabolic surgery also be
considered to be an option to treat T2MD in patients
with BMI 30.0–34.9 kg/m2 or 27.5–32.4 kg/m2 in Asian
descent, and inadequately controlled hyperglycemia des-
pite optimal medical treatment by either oral or inject-
able insulin during Diabetes Surgery Summit II [54].
This investigation reveals interesting results that the
research of laparoscopic metabolic surgery for T2DM
with BMI of > 25 kg/m2 to < 35 kg/m2 has increased in
Asian countries (Fig. 2; Table 3), and all studies had an
acceptable diabetes mellitus resolution (remission rate
range from 52.9 to 96.2% at 1, 3, or 5 years). A
meta-analysis including nine trials (from China, USA,
Chile, Brazil and Spain) with T2DM and BMI < 35 kg/
m2 undergoing LRYGB, suggested that these patients
had a significant decrease in BMI (P < 0.00001),
remission of diabetes (glucose, P < 0.00001, hemoglobin
A1c, P < 0.00001) at 12 months follow-up [58]. Lee et al.
[38] investigated 201 patients with impaired fasting glu-
cose or T2DM undergoing laparoscopic mini-gastric by-
pass, and showed that 76.5% patients with 25 kg/m2 <
BMI < 35 kg/m2 met treatment goals (HbA1C < 7%,
LDL < 150 mg/dl, triglyceride <150 mg/dl) compared
with 92.4% patients with BMI > 35 kg/m2. Although, all
16 studies in our review showed that laparoscopic meta-
bolic surgery is effective for patients with BMI of >
25 kg/m2 to < 35 kg/m2 in Asian countries, further re-
search is needed to determine whether these effects are
universal across other countries. Moreover, there were
no mortalities nor severe complications reported in any
of trials (Table 3) [23–38]. And the Table 3 showed that
most surgery for T2DM with low BMI were performed
in East Asia, which is correlated with a lower BMI than
in European/western patients, the risk of T2DM in
different ethnics is different. In Asia, the related
complication of T2DM occurred when BMI is not high.
This might also influences indication for “diabetes-sur-
gery” [18, 59–61].
This review has some limitations: Firstly, this study
only analyzed the Asian literature from a single data-
base, PubMed, and might not include studies pub-
lished in other regional or national databases.
Secondly, we could not perform a meta-analysis in
our present study to compare the differences between
low and high (BMI > 25 kg/m2 to < 35 kg/m2 vs
BMI ≥ 35 kg/m2) and other characteristics due to
heterogeneity of the reports. Thirdly, there is a lack
of well-designed rigorous randomized controlled trials
investigating this intervention, and therefore a paucity
of high-level evidence to support any recommenda-
tions. Therefore, further research is obligatory to
understand long-term health outcomes, improvements
and sustainability of the glycemic control and advance
surgical procedures.
Conclusions
This review demonstrated that SLG and LRYGBP are
the two commonly used surgical procedures for T2DM
patients with comorbid obesity in Asia. Laparoscopic
metabolic surgery can be performed in T2DM patients
with BMI of > 25 kg/m2 to < 35 kg/m2. However, there
is a need for further research to identify long-term com-
plications, sustained rates of diabetes resolution, and
promotion of the further development of metabolic sur-
gery in Asia.
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